← All trials
NCT02830360
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 1, 2016
- Primary completion
- Oct 1, 2018
- Completion date
- Oct 1, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 75
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Nova Scotia Health AuthorityLead sponsor
- Government of CanadaOverall official - principal investigator
- Government of CanadaSponsor investigator
- University of OttawaStudy director
- Harvard UniversityStudy director
- Government of CanadaStudy director
- McMaster UniversityStudy director
- St. Jude MedicalCollaborator
- Biosense Webster, Inc.Collaborator
- University of OttawaCollaborator
- Heart and Stroke Foundation of CanadaCollaborator
- University of Western OntarioStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.